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Background:  Latent autoimmune diabetes in adults (LADA) refers to a specific type of diabetes characterized by adult onset, 
presence of islet auto-antibodies, insulin independence at the time of diagnosis, and rapid decline in β-cell function. The preva-
lence of LADA among patients with type 2 diabetes varies from 2% to 20% according to the study population. Since most studies 
on the prevalence of LADA performed in Korea were conducted in patients who had been tested for anti-glutamic acid decar-
boxylase antibody (GADAb), a selection bias could not be excluded. In this study, we examined the prevalence and clinical char-
acteristics of LADA among adult patients recently diagnosed with type 2 diabetes. 
Methods:  We included 462 patients who were diagnosed with type 2 diabetes within 5 years from the time this study was per-
formed. We measured GADAb, fasting insulin level, fasting C-peptide level, fasting plasma glucose level, HbA1c, and serum lip-
id profiles and collected data on clinical characteristics. 
Results:  The prevalence of LADA was 4.3% (20/462) among adult patients with newly diagnosed type 2 diabetes. Compared 
with the GADAb-negative patients, the GADAb-positive patients had lower fasting C-peptide levels (1.2±0.8 ng/mL vs. 2.0±1.2 
ng/mL, P=0.004). Other metabolic features were not significantly different between the two groups. 
Conclusion:  The prevalence of LADA is 4.3% among Korean adult patients with recently diagnosed type 2 diabetes. The Korean 
LADA patients exhibited decreased insulin secretory capacity as reflected by lower C-peptide levels.
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INTRODUCTION
Type 1A diabetes mellitus is caused by the autoimmune de-
struction of pancreatic β-cells, which leads to insulin deficien-
cy resulting in a need for insulin therapy for most patients. 
Pancreatic auto-antibodies, such as islet cell cytoplasmic anti-
body (ICA) [1], glutamic acid decarboxylase antibody (GAD-
Ab) [2], and antibodies to the protein tyrosine phosphatases 
IA-2 or IA-2β, are used to diagnose type 1A diabetes [3]. How-
ever, as in typical cases of type 1A diabetes, some patients clin-
ically diagnosed with type 2 diabetes have circulating auto-an-
tibodies to pancreatic β-cells [4-7]. Type 2 diabetes with posi-
tive auto-antibodies is characterized by insulin independence 
at the time of diagnosis, a high incidence of relative insulin de-
ficiency and rapid progression to insulin dependence [5-9]. This 
form of diabetes has also been called latent autoimmune dia-
betes in adults (LADA) [8], slowly progressive insulin-depen-
dent diabetes mellitus [10] or type 1.5 diabetes [11]. LADA has 
been included in the proposal for the World Health Organiza-
tion (WHO) criteria for diabetes as a subgroup of type 1 dia-
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betes [12].
  In the United Kingdom Prospective Diabetes Study (UKP-
DS), 10% of patients were positive for GADAb, and 52% of pa-
tients with a titer of GADAb ≥20 U/L required insulin treat-
ment within 6 years after diagnosis [7]. Fourlanos et al. [13] 
found that LADA was commonly associated with the follow-
ing clinical features: age of onset <50 years, acute onset of symp-
toms, body mass index (BMI) <25 kg/m
2, and personal histo-
ry or family history of autoimmune diseases.
  There is a controversy about whether LADA can be viewed 
as a separate form of diabetes or rather a subgroup of type 1 
diabetes [14]. Patients with LADA have a similar disease pro-
cess as patients with type 1 diabetes in that they have a higher 
rate of progression to insulin dependency and a lower preva-
lence of metabolic syndrome [15,16]. However, LADA exhib-
its a slower progression toward insulin dependency compared 
to typical type 1 diabetes and also shows clinical features of in-
sulin resistance. Recent studies reported that LADA shares ge-
netic features of both type 1 and type 2 diabetes [17,18]. There-
fore, LADA is considered a specific form of diabetes that lies 
somewhere between type 1 and type 2 diabetes [18].
  In Korea, several studies have examined the prevalence and 
clinical characteristics of LADA [19-24]. However, the number 
of patients in most of these studies was small, and the study 
patients were tested for GADAb probably due to suspicion of a 
diagnosis other than type 2 diabetes. Thus, these studies had a 
limitation to represent the prevalence or clinical characteristics 
of LADA in Koreans. In this study, we measured GADAb in 
patients with recent onset type 2 diabetes and evaluated the 
prevalence of GADAb positivity and compared the clinical 
characteristics of patients with and without GADAb. 
METHODS
Participants
This study was approved by the Institutional Review Board of 
Seoul National University Hospital (H-1106-127-369). Between 
January 2005 and July 2007, we tested GADAb in 749 patients 
over 20 years of age who first visited the Diabetes Clinic of 
Seoul National University Hospital. We selected 527 patients 
who were diagnosed with diabetes within the past 5 years and 
excluded patients with type 1 diabetes, those who started insu-
lin therapy within 1 year after diagnosis of diabetes, and pa-
tients with a history of diabetic ketoacidosis. We also excluded 
patients who were pregnant, had chronic liver disease, acute 
infection, history of organ transplantation, current chemother-
apy for malignancy, or other conditions that could affect glucose 
metabolism. Therefore, a total of 462 patients were included in 
the analysis.
Methods 
GADAb test
GADAb was measured by a radioimmunoassay employing 
125I-labeled human recombinant GAD65 manufactured by 
RSR (Cardiff, Wales, UK). GADAb values >1.0 U/mL were 
considered positive.
Laboratory methods
Biochemical tests (such as serum levels of glucose and lipids) 
were measured with the Toshiba 200FR Neo Chemistry auto-
analyzer (Toshiba Medical Systems Co., Tokyo, Japan) after 
overnight fasting. Hemoglobin A1c (HbA1c) was determined 
by an affinity chromatography (Bio-Rad Laboratories, Hercu-
les, CA, USA), and the C-peptide level was evaluated with a 
radioimmunoassay (TFB, Tokyo, Japan). The serum insulin 
concentration was measured using a immunoradiometric as-
say (Biosource Europe S.A., Nivelles, Belgium). Insulin resis-
tance and β-cell function were estimated using homeostasis 
model assessment (HOMA-IR and HOMA-β, respectively) 
[25].
Physical examination
We measured height, weight, and blood pressure with standard 
methods. The waist circumference across the area midway be-
tween the lowest rib margin and the highest point of the iliac 
crest and the hip circumference across the widest level over both 
the greater trochanters were measured.
Statistical analysis
Statistical analyses were performed using the SPSS (SPSS Inc., 
Chicago, IL, USA). Data are given as the mean±standard de-
viation. χ
2-test, Fisher’s exact test, Student’s t-test, and Mann-
Whitney U test were used where appropriate. A two-tailed P 
value less than 0.05 was considered statistically significant.
RESULTS
Prevalence of GADAb positivity
Of 462 patients, 20 (4.3%) were positive for GADAb. The 
GADAb positivity among men and women was 4.6% (12/260) 138
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and 4.0% (8/202), respectively. GADAb was found in 9% to 
10% of patients in their 20s or 30s, less than 4% in patients in 
their 40s, 50s or 60s, and in 5% of patients over 70 (Fig. 1).
Clinical characteristics of type 2 diabetic patients according 
to presence of GADAb
The mean ages of the patients with positive GADAb (n=20) 
and negative GADAb (n=442) were 52.3±14.1 and 55.3±11.6, 
respectively. There was no difference in age, age at the time of 
diagnosis of diabetes, or the duration of diabetes between 
GADAb-positive and GADAb-negative patients. Proportions 
of patients taking antihypertensive medication or 3-hydroxy-
3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibi-
tor were not different in the groups. Three of 20 (15.0%) GAD-
Ab-positive patients required insulin treatment compared to 
24 of 442 (5.4%) GADAb-negative patients, a difference which 
was only marginally significant (P=0.074).
  BMI values were not statistically different between the two 
groups (23.7±3.6 kg/m
2 vs. 25.2±3.6 kg/m
2, P=0.101), al-
though BMI tended to be lower in patients with positive GAD-
Ab. C-peptide levels were significantly lower in GADAb-posi-
tive patients than in GADAb-negative patients (1.2±0.8 ng/mL 
vs. 2.0±1.2 ng/mL, P=0.004). The two groups did not differ 
with respect to waist circumference, waist-to-hip circumfer-
ence ratio, systolic blood pressure, diastolic blood pressure, 
fasting insulin levels, HbA1c, fasting glucose levels, or serum 
lipid profile (including total cholesterol, triglyceride, high den-
sity lipoprotein cholesterol [HDL-C], and low density lipopro-
tein cholesterol [LDL-C]). GADAb-positive and GADAb-neg-
ative patients had similar values of HOMA-insulin resistance 
(IR) and HOMA β-cell function (Table 1).
  According to the titer of GADAb, we divided the LADA pa-
tients into high- (≥10 U/mL) and low-titer (<10 U/mL) sub-
groups, which was a similar analytic approach as that used in a 
previous study [26]. C-peptide levels were higher in LADA 
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Fig. 1.  The prevalence of glutamic acid decarboxylase anti-
body (GADAb)-positivity per age group. GADAb was found 
in 9% to 10% of patients in their 20s or 30s, whereas it was 
identified in less than 5% of patients older than 40 years.
Table 1.  Clinical characteristics of recently diagnosed type 2 di-
abetic patients according to the presence or absence of GADAb
Characteristic GADAb (+) GADAb (-) P value
No. 20 442
Sex, M/F 12/8 248/194 0.731
Age at study, yr 52.3±14.1 55.3±11.6 0.253
Age at onset, yr 50.0±14.4 53.6±11.6 0.180
Duration of diabetes, yr 2.3±1.3 1.7±1.6 0.123
BMI, kg/m
2 23.7±3.6 25.2±3.6 0.101
Systolic blood pressure,  
mm Hg
120.5±10.1 126.3±13.0 0.063
Diastolic blood pressure,  
mm Hg
70.0±6.1 74.3±9.2 0.051
Waist circumference, cm 87.1±7.2 86.5±8.7 0.795
Waist-to-hip ratio 0.91±0.03 1.15±4.77 0.846
Fasting plasma C-peptide,  
ng/mL
1.2±0.8 2.0±1.2 0.004
Fasting plasma insulin,  
μU/mL
9.6±3.9 13.4±8.4 0.055
HOMA-IR 3.5±1.8 4.5±3.8 0.242
HOMA-β cell function 51.6±29.1 83.4±82.8 0.096
HbA1c, % 8.0±2.4 7.5±1.6 0.407
Fasting plasma glucose,  
mg/dL
147.3±43.1 135.8±41.3 0.225
Total cholesterol, mg/dL 178.8±43.1 185.9±41.5 0.449
Triglycerides, mg/dL 124.8±47.0 172.9±147.3 0.146
HDL-C, mg/dL 50.7±12.7 47.8±12.7 0.324
LDL-C, mg/dL 107.9±36.2 110.6±37.2 0.756
No. of patients using  
insulin (%)
3 (15.0) 24 (5.4) 0.074
No. of patients using  
antidiabetic drugs (%)
8 (40.0) 124 (28.1) 0.247
No. of patients using  
antihypertensive drugs (%)
6 (30.0) 166 (37.6) 0.494
No. of patients using  
statins (%)
4 (20.0) 127 (28.7) 0.397
Values are presented as mean±standard deviation or number (%).
GADAb, glutamic acid decarboxylase antibody; BMI, body mass in-
dex; HOMA-IR, homeostasis model assessment of insulin resistance; 
HDL-C, high density lipoprotein cholesterol; LDL-C, low density li-
poprotein cholesterol; statins, HMG-CoA reductase inhibitors.139
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patients with a low-titer of GADAb than in those with a high-
titer of GADAb. The HDL-C and LDL-C concentrations were 
higher in the LADA patients with a high titer of GADAb than 
in those with a low titer of GADAb. The LADA patients with a 
high titer of GADAb were more likely to require insulin than 
those with a low titer of GADAb (Table 2). 
DISCUSSION
Type 1A diabetes mellitus results from the autoimmune de-
struction of insulin-producing β-cells in pancreatic islets. ICA 
and GADAb are markers of autoimmunity and are detected in 
70% to 80% of patients with type 1 diabetes [27]. LADA is de-
fined as the initially non-insulin-requiring condition of diabe-
tes with autoimmune markers of type 1 diabetes, such as ICA 
and GADAb. Progressive β-cell destruction by autoimmune 
mechanisms is considered as the main pathogenesis of LADA 
[28,29]. IA-2 antibody is detected in a high frequency at diag-
nosis in type 1 diabetic children, whereas the frequency is low-
er in LADA patients [30]. In addition, GADAb has a higher 
sensitivity compared with ICA [9,17]. Therefore, we used 
GADAb to identify cases with LADA in this study.
  In previous studies performed in Korea, the prevalence of 
GADAb-positivity in type 2 diabetes was reported to be 1.7% 
to 12.6% [19-24]. In the current study, 4.3% of patients were 
positive for GADAb, which represents similar findings as those 
reported by Ko et al. [22], Oh et al. [24], and Lee et al. [31]. Most 
previous Korean studies selected patients who were non-obese 
or patients tested for GADAb who were under clinical suspi-
cion of a diagnosis other than type 2 diabetes. In our study, we 
tested GADAb in all type 2 diabetic patients with a recent on-
set (within the past 5 years) regardless of their clinical charac-
teristics at the time of presentation, which might help us avoid 
selection bias and therefore more accurately estimate the un-
biased prevalence of LADA. 
  The prevalence of GADAb-positivity in this study was simi-
lar to the prevalence in Japanese studies [32,33]; however, it 
was lower than that reported in China [34] or Western coun-
tries [7,17]. The prevalence of LADA has been estimated in a 
number of studies (including large-scale studies) [7,35], re-
vealing a wide range of variations from 2% to 20% (Table 3). 
The prevalence of LADA has been shown to vary even within 
the same country. In Swedish studies, the frequency of LADA 
ranged from 8% to 24%. A wide range of variation in the prev-
alence of LADA within a country or across countries may de-
pend on criteria for diagnosis, antibody assay methods, char-
acteristics of the patients, and genetic susceptibility. 
Table 2. Clinical characteristics of LADA patients according 
to GADAb titer
Characteristic
Low titer 
(<10 U/mL)
 High titer 
(≥10 U/mL)
P value
No. 14 6
GADAb titer, U/mL 2.3±1.2 233.9±436.2 0.000
Age at study, yr 52.2±14.1 52.3±15.6 0.968
Age at onset, yr 50.1±14.2 49.8±16.2 0.968
Duration of diabetes, yr 2.1±1.1 2.5±1.9 0.718
BMI, kg/m
2 23.9±4.0 23.4±3.1 0.750
Systolic blood pressure,  
mm Hg
119.3±9.0 122.8±12.6 0.494
Diastolic blood pressure,  
mm Hg
68.3±4.2 73.5±8.0 0.083
Waist circumference, cm 85.8±6.6 90.5±8.4 0.454
Waist-to-hip ratio 0.90±0.03 0.92±0.05 0.240
Fasting plasma  
C-peptide, ng/mL
1.54±0.68 0.46±0.50 0.002
Fasting plasma insulin,  
μU/mL
10.3±4.4 8.2±2.3 0.416
HOMA-IR 3.5±2.1 3.4±1.3 0.701
HOMA-β cell function 54.4±19.8 45.5±45.1 0.210
HbA1c, % 7.5±1.7 9.2±3.3 0.239
Fasting plasma glucose,  
mg/dL
135.4±25.4 175.2±63.7 0.207
Total cholesterol, mg/dL 166.4±40.3 207.5±37.9 0.109
Triglycerides, mg/dL 135.1±46.3 100.7±42.8 0.274
HDL-C, mg/dL 47.0±12.0 59.3±10.7 0.026
LDL-C, mg/dL 99.4±11.9 127.7±32.5 0.041
No. of patients using  
insulin (%)
0 (0) 3 (50.0) 0.018
No. of patients using  
oral antidiabetic drugs (%)
7 (50.0) 1 (16.7) 0.325
No. of patients using  
antihypertensive drugs (%)
5 (35.7) 1 (16.7) 0.613
No. of patients using  
statins (%)
3 (21.4) 1 (16.7) 1.000
Statistical significance was determined by Mann-Whitney U test or 
Fisher’s exact test.
Values are presented as mean±standard deviation or number (%).
LADA, latent autoimmune diabetes in adults; GADAb, glutamic acid 
decarboxylase antibody; BMI, body mass index; HOMA-IR, homeo-
stasis model assessment of insulin resistance; HDL-C, high density li-
poprotein cholesterol; LDL-C, low density lipoprotein cholesterol; 
statins, HMG-CoA reductase inhibitors.140
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  In previous studies of Western countries, LADA patients 
have a lower BMI, more decreased insulin secretory capacity 
at diagnosis, and more rapid progression to insulin dependence 
than typical type 2 diabetes patients [7,9,17]. In the current 
study, the BMI of the patients with positive GADAb tended to 
be lower than that of the patients with negative GADAb, which 
was not a statistically significant difference. In addition, com-
ponents of metabolic syndrome, such as hypertension, hyper-
cholesterolemia, abdominal obesity, and fasting hyperglyce-
mia, were evaluated in this study. No difference was seen be-
tween GADAb-positive and GADAb-negative patients with 
respect to the use of antihypertensive medication or HMG-CoA 
reductase inhibitors; serum levels of fasting glucose, triglycer-
ides, total cholesterol, LDL-C, and HDL-C; or waist circum-
ference and waist-to-hip circumference ratio. Patients with 
GADAb tended to have higher systolic and diastolic blood 
pressure than patients without GADAb. However, these differ-
ences were not statistically significant. These results were con-
trary to the findings of other studies. Tuomi et al. [17] report-
ed that patients with GADAb had lower blood pressure, a low-
er level of triglycerides, and a lower waist-to-hip circumfer-
ence ratio compared with patients without GADAb. The 
ADOPT study revealed that patients with positive GADAb 
had a higher level of serum HDL-C, lower serum triglyceride 
levels, and a lower prevalence of metabolic syndrome than pa-
tients with negative GADAb [35]. In another study performed 
in Caucasian populations, metabolic syndrome was more fre-
quent in type 2 diabetes patients without GADAb than it was 
in LADA patients [16]. The mean BMI of our study patients 
was 25.3 kg/m
2, which is lower than that of Western studies 
(27.5 to 32 kg/m
2) [7,17,35] and may explain different features 
related to metabolic syndrome among different ethnic groups. 
In this study, however, many patients without GADAb were 
treated with HMG-CoA reductase inhibitors, which might have 
contributed to attenuating the difference in lipid profiles ac-
cording to the presence of GADAb. Nonetheless, even though 
there was no difference in the use of HMG-CoA reductase in-
hibitors between high- and low-GADAb titer groups, the HDL-
Table 3. Prevalence of GADAb in adult patients with clinical features of type 2 diabetes
Author Country Study type Age Participants (n) Other inclusions Prevalence
Current study Korea Clinic referrals ≥20 T2DM (462) 4.3%
Park et al. [19] Korea Population-based New NIR (121) 1.7%
Ko et al. [22] Korea Clinic referrals New NIR (245) 4.0%
Kim et al. [23] Korea Clinic referrals ≥25 T2DM (428) BMI  
≤ 25 (kg/m
2)
12.6%
Oh et al. [24] Korea Clinic referrals New NIR (267) Use of sulfonyl-
urea
4.1%
Lee et al. [31] Korea Clinic referrals ≥25 T2DM (9,250) 4.7%
Bosi et al. [37] Italy Population-based >40 (2,076) 2.8% in diabetic patients,  
1% in normal controls
Tuomi et al. [17] Finland Population-based 28-83 All NIR (1,122) 9.3%
Turner et al. [7] UK Representative pop-
ulation
25-65 New NIR (3,672) Caucasian 10.0%
Ruige et al. [38] Holland Population sample 50-74 General population,  
all known diabetics, 
screened diabetics (2,350)
0.7 in normal controls, 3.5% 
in known diabetics, 0% in 
newly detected diabetics
Niskanen et al. [9] Finland General practitioner 
referrals from de-
fined population
45-64 New NIR (133) 9.0%
Takeda et al. [32] Japan Clinic referrals >20 (4,980) 3.8%
Zinman et al. [35] North Ameri-
ca, Europe 
Population-based 30-75 New NIR (4,134) FBG 7.0-10.0 
(mmol/L)
4.2%
GADAb, glutamic acid decarboxylase antibody; NIR, non-insulin-requiring diabetes; BMI, body mass index; T2DM, type 2 diabetes; FBG, 
fasting blood glucose.141
Prevalence and characteristics of LADA
Diabetes Metab J 2012;36:136-143 http://e-dmj.org
C and LDL-C concentrations were lower in LADA patients 
with a low titer of GADAb than they were in those with high 
GADAb titers. The apparent absence of an association between 
LADA and the features of metabolic syndrome may be due to 
the small number of participants in our study. Therefore, a 
large-scale, nationwide study is warranted to examine the 
clinical characteristics related to metabolic syndrome in pa-
tients with LADA in Korea. 
  We observed that GADAb-positive patients had lower C-
peptide levels than GADAb-negative patients, which suggests 
that β-cell destruction by autoimmunity may elicit decreased 
insulin secretory capacity in patients with LADA [31]. In ad-
dition, patients who were positive for GADAb tended to use 
insulin more frequently than patients who were negative for 
GADAb. Furthermore, the LADA patients with a high titer of 
GADAb obviously needed more insulin therapy and had lower 
C-peptide levels than the LADA patients with a low titer of 
GADAb, which was consistent with the results of a previous 
study [17]. Because patients with LADA also exhibit insulin 
resistance like that in type 2 diabetic patients, they may require 
a different therapeutic approach than the usual type 2 diabetic 
patients. Sulfonylureas are generally not recommended as the 
first-line therapy for LADA because these drugs may bring 
about earlier insulin dependence [36]. As was shown in the 
present study, the clinical characteristics of LADA in Korea may 
be different from those in Western countries; it may be neces-
sary to develop a therapeutic strategy unique to Korean patients. 
  In conclusion, we showed that the prevalence of LADA was 
4.3% among recently diagnosed type 2 diabetic patients in Ko-
rea. The Korean LADA patients exhibited decreased insulin 
secretory capacity in terms of C-peptide level. Considering the 
unique pathogenetic mechanism of LADA, encompassing not 
only prominent insulin deficiency but also insulin resistance, 
it is mandatory to develop an effective therapy to reduce hy-
perglycemia and to halt the progressive beta-cell failure in 
these patients.
CONFLICTS OF INTEREST
No potential conflict of interest relevant to this article was re-
ported.
ACKNOWLEDGMENTS
This study was supported by Grant 00-PJ3-PG6-GN07-001 
from the Genome Research Center for Diabetes and Endocrine 
Disease, Ministry of Health & Welfare, Republic of Korea.
REFERENCES
1. MacCuish AC, Irvine WJ, Barnes EW, Duncan LJ. Antibodies 
to pancreatic islet cells in insulin-dependent diabetics with co-
existent autoimmune disease. Lancet 1974;2:1529-31.
2. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, 
Cascalho M, Folli F, Richter-Olesen H, De Camilli P. Identifi-
cation of the 64K autoantigen in insulin-dependent diabetes as 
the GABA-synthesizing enzyme glutamic acid decarboxylase. 
Nature 1990;347:151-6.
3. American Diabetes Association. Diagnosis and classification 
of diabetes mellitus. Diabetes Care 2011;34 Suppl 1:S62-9.
4. Irvine WJ, McCallum CJ, Gray RS, Duncan LJ. Clinical and 
pathogenic significance of pancreatic-islet-cell antibodies in 
diabetics treated with oral hypoglycaemic agents. Lancet 1977; 
1:1025-7.
5. Gottsater A, Landin-Olsson M, Fernlund P, Lernmark A, Sun-
dkvist G. Beta-cell function in relation to islet cell antibodies 
during the first 3 yr after clinical diagnosis of diabetes in type 
II diabetic patients. Diabetes Care 1993;16:902-10.
6. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, 
Mackay IR. Antibodies to glutamic acid decarboxylase reveal 
latent autoimmune diabetes mellitus in adults with a non-in-
sulin-dependent onset of disease. Diabetes 1993;42:359-62.
7. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay 
IR, Shattock M, Bottazzo GF, Holman R. UKPDS 25: autoanti-
bodies to islet-cell cytoplasm and glutamic acid decarboxylase 
for prediction of insulin requirement in type 2 diabetes. UK 
Prospective Diabetes Study Group. Lancet 1997;350:1288-93.
8. Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, 
Cohen M, Lang DA. Latent autoimmune diabetes mellitus in 
adults (LADA): the role of antibodies to glutamic acid decar-
boxylase in diagnosis and prediction of insulin dependency. 
Diabet Med 1994;11:299-303.
9. Niskanen LK, Tuomi T, Karjalainen J, Groop LC, Uusitupa MI. 
GAD antibodies in NIDDM. Ten-year follow-up from the di-
agnosis. Diabetes Care 1995;18:1557-65.
10. Groop L, Groop PH, Koskimies S. Relationship between B-cell 
function and HLA antigens in patients with type 2 (non-insu-
lin-dependent) diabetes. Diabetologia 1986;29:757-60.
11. Juneja R, Palmer JP. Type 1 1/2 diabetes: myth or reality? Auto-
immunity 1999;29:65-83.142
Hwangbo Y, et al.
Diabetes Metab J 2012;36:136-143 http://e-dmj.org
12. World Health Organization Department of Noncommunica-
ble Disease Surveillance. Definition, diagnosis and classifica-
tion of diabetes mellitus and its complications: report of a WHO 
consultation. Part 1, diagnosis and classification of diabetes 
mellitus. Geneva: World Health Organization; 1999. p59.
13. Fourlanos S, Perry C, Stein MS, Stankovich J, Harrison LC, 
Colman PG. A clinical screening tool identifies autoimmune 
diabetes in adults. Diabetes Care 2006;29:970-5.
14. Gale EA. Latent autoimmune diabetes in adults: a guide for the 
perplexed. Diabetologia 2005;48:2195-9.
15. Hosszufalusi N, Vatay A, Rajczy K, Prohaszka Z, Pozsonyi E, 
Horvath L, Grosz A, Gero L, Madacsy L, Romics L, Karadi I, 
Fust G, Panczel P. Similar genetic features and different islet 
cell autoantibody pattern of latent autoimmune diabetes in 
adults (LADA) compared with adult-onset type 1 diabetes 
with rapid progression. Diabetes Care 2003;26:452-7.
16. Hawa MI, Thivolet C, Mauricio D, Alemanno I, Cipponeri E, 
Collier D, Hunter S, Buzzetti R, de Leiva A, Pozzilli P, Leslie 
RD; Action LADA Group. Metabolic syndrome and autoim-
mune diabetes: action LADA 3. Diabetes Care 2009;32:160-4.
17. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, 
Nissen M, Ehrnstrom BO, Forsen B, Snickars B, Lahti K, Fors-
blom C, Saloranta C, Taskinen MR, Groop LC. Clinical and 
genetic characteristics of type 2 diabetes with and without GAD 
antibodies. Diabetes 1999;48:150-7.
18. Cervin C, Lyssenko V, Bakhtadze E, Lindholm E, Nilsson P, 
Tuomi T, Cilio CM, Groop L. Genetic similarities between la-
tent autoimmune diabetes in adults, type 1 diabetes, and type 
2 diabetes. Diabetes 2008;57:1433-7.
19. Park Y, Lee H, Koh CS, Min H, Rowley M, Mackay IR, Zimmet 
P, McCarthy B, McCanlies E, Dorman J, Trucco M. The low 
prevalence of immunogenetic markers in Korean adult-onset 
IDDM patients. Diabetes Care 1996;19:241-5.
20. Kim KA, Ahn KJ, Chung JH, Min YK, Lee MK, Oh PS, Jin DK, 
Kim BT, Park HJ, Kim KW, Lee MS. Combined measurements 
of anti-ICA512 and anti-GAD antibodies in insulin-dependent 
diabetes mellitus and slowly progressive insulin-dependent di-
abetes mellitus in Korea. J Korean Diabetes Assoc 1998;22: 
484-5.
21. Lee HH, Shin YG, Kim HS, Kim CY, Jeong YS, Kim HS, Park 
DW, Yoon KJ, Chung CH. Measurement of anti-GAD antibody 
by EIA and RIA methods in Korean diabetic patients: study for 
pathogenesis of slowly progressive IDDM. J Korean Diabetes 
Assoc 1997;21:234-5.
22. Ko KS, Hong SK, Lee KU, Kim NH, Choi DS, Ihm SH, Park 
SW, Kim CH, Byun DW, Suh KI, Chang HC, Rhee BD. The 
frequency of ICA and anti-GAD antibody in Korean IDDM 
and NIDDM patients. J Korean Diabetes Assoc 1998;22:313-4.
23. Kim CS, Park JA, Cho MH, Park JS, Nam JY, Kim DM, Ahn 
CW, Cha BS, Lim SK, Kim KR, Lee HC. The frequency of anti-
GAD antibody in non-obese, adult-onset type 2 diabetes in 
Korea and clinical and biological characteristics according to 
anti-GAD antibody. J Korean Diabetes Assoc 2004;22:66-74.
24. Oh JH, Yoon JS, Won KC, Lee HW. Antibodies to GAD and 
ICA in type 2 DM with secondary failure of oral hypoglycemic 
therapy. J Korean Diabetes Assoc 2007;31:402-9.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher 
DF, Turner RC. Homeostasis model assessment: insulin resis-
tance and beta-cell function from fasting plasma glucose and 
insulin concentrations in man. Diabetologia 1985;28:412-9.
26. Kasuga A, Maruyama T, Nakamoto S, Ozawa Y, Suzuki Y, Sa-
ruta T. High-titer autoantibodies against glutamic acid decar-
boxylase plus autoantibodies against insulin and IA-2 predicts 
insulin requirement in adult diabetic patients. J Autoimmun 
1999;12:131-5.
27. Riley WJ, Maclaren NK, Krischer J, Spillar RP, Silverstein JH, 
Schatz DA, Schwartz S, Malone J, Shah S, Vadheim C, Rotter 
JI. A prospective study of the development of diabetes in rela-
tives of patients with insulin-dependent diabetes. N Engl J Med 
1990;323:1167-72.
28. Pozzilli P, Di Mario U. Autoimmune diabetes not requiring in-
sulin at diagnosis (latent autoimmune diabetes of the adult): 
definition, characterization, and potential prevention. Diabe-
tes Care 2001;24:1460-7.
29. Fourlanos S, Dotta F, Greenbaum CJ, Palmer JP, Rolandsson O, 
Colman PG, Harrison LC. Latent autoimmune diabetes in 
adults (LADA) should be less latent. Diabetologia 2005;48: 
2206-12.
30. Naik RG, Palmer JP. Latent autoimmune diabetes in adults 
(LADA). Rev Endocr Metab Disord 2003;4:233-41.
31. Lee SA, Kim EY, Kim EH, Jeong JY, Jeong EH, Kim DW, Cho 
EH, Koh EH, Joong MS, Park Y, Lee KU. Anti-GAD antibody 
in patients with adult-onset diabetes in Korea. J Korean Diabe-
tes Assoc 2009;33:16-23.
32. Takeda H, Kawasaki E, Shimizu I, Konoue E, Fujiyama M, 
Murao S, Tanaka K, Mori K, Tarumi Y, Seto I, Fujii Y, Kato K, 
Kondo S, Takada Y, Kitsuki N, Kaino Y, Kida K, Hashimoto N, 
Yamane Y, Yamawaki T, Onuma H, Nishimiya T, Osawa H, 
Saito Y, Makino H; Ehime Study. Clinical, autoimmune, and 
genetic characteristics of adult-onset diabetic patients with 143
Prevalence and characteristics of LADA
Diabetes Metab J 2012;36:136-143 http://e-dmj.org
GAD autoantibodies in Japan (Ehime Study). Diabetes Care 
2002;25:995-1001.
33. Fukui M, Nakano K, Shigeta H, Yoshimori K, Fujii M, Kitaga-
wa Y, Mori H, Kajiyama S, Nakamura N, Abe N, Obayashi H, 
Fukui I, Ohta K, Ohta M, Kondo M. Antibodies to glutamic 
acid decarboxylase in Japanese diabetic patients with second-
ary failure of oral hypoglycaemic therapy. Diabet Med 1997;14: 
148-52.
34. Thai AC, Ng WY, Loke KY, Lee WR, Lui KF, Cheah JS. Anti-
GAD antibodies in Chinese patients with youth and adult-on-
set IDDM and NIDDM. Diabetologia 1997;40:1425-30.
35. Zinman B, Kahn SE, Haffner SM, O’Neill MC, Heise MA, Freed 
MI; ADOPT Study Group. Phenotypic characteristics of GAD 
antibody-positive recently diagnosed patients with type 2 dia-
betes in North America and Europe. Diabetes 2004;53:3193-
200.
36. Brophy S, Brunt H, Davies H, Mannan S, Williams R. Inter-
ventions for latent autoimmune diabetes (LADA) in adults. 
Cochrane Database Syst Rev 2007;(3):CD006165.
37. Bosi EP, Garancini MP, Poggiali F, Bonifacio E, Gallus G. Low 
prevalence of islet autoimmunity in adult diabetes and low 
predictive value of islet autoantibodies in the general adult 
population of northern Italy. Diabetologia 1999;42:840-4.
38. Ruige JB, Batstra MR, Aanstoot HJ, Bouter LM, Bruining GJ, 
De Neeling JN, Heine RJ. Low prevalence of antibodies to 
GAD65 in a 50- to 74-year-old general Dutch population. The 
Hoorn Study. Diabetes Care 1997;20:1108-10.